BrightSpring Health Services Inc
For the period ended Mar 31, 2024. Filed May 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 2, 2024
BTSG$69.15+3.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders' Equity
(In thousands, except share data or otherwise indicated)
| Common Stock · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · NoncontrollingInterest · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||
| Balances at December 31, 2023 | 117,857,055 | $1,179 | $771,336 | $(200,319) | $12,544 | $670 | $585,410 |
| Net loss (1) | — | — | — | (45,750) | — | (152) | (45,902) |
| Other comprehensive income, net of tax | — | — | — | — | 10,571 | — | 10,571 |
| Share-based compensation | — | — | 24,848 | — | — | — | 24,848 |
| Extinguishment of redeemable noncontrolling interest | — | — | 14,981 | — | — | — | 14,981 |
| Issuance of common stock on initial public offering, net of underwriting discounts and commissions, and offering-related expenses of $36.8 million | 53,333,334 | 533 | 655,952 | — | — | — | 656,485 |
| Proceeds from stock purchase contract issued under tangible equity units, net of underwriting discounts and commissions of $9.1 million | — | — | 321,611 | — | — | — | 321,611 |
| Balances at March 31, 2024 | 171,190,389 | $1,712 | $1,788,728 | $(246,069) | $23,115 | $518 | $1,568,004 |
| Common Stock · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · NoncontrollingInterest · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||
| Balances at December 31, 2022 | 117,860,839 | $1,179 | $778,121 | $(45,716) | $21,192 | $— | $754,776 |
| Net loss (1) | — | — | — | (21,382) | — | — | (21,382) |
| Other comprehensive loss, net of tax | — | — | — | — | (10,211) | — | (10,211) |
| Share-based compensation | — | — | 450 | — | — | — | 450 |
| Shares issued under share-based compensation plan, including tax effects | 22,392 | — | 145 | — | — | — | 145 |
| Balances at March 31, 2023 | 117,883,231 | $1,179 | $778,716 | $(67,098) | $10,981 | $— | $723,778 |
(1) Net loss to the Company for the three months ended March 31, 2024 and 2023 excludes $(483) and $(894), respectively, allocable to the redeemable noncontrolling interests for our joint venture arrangements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.